Analysis Tools|
Allele Symbol Allele Name Allele ID |
Nbn+ wild type MGI:2438585 |
||||||||||||||||||||
| Summary |
4 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• heterozygotes irradiated with gamma-rays at a dosage of 8 Gy exhibit a significantly shorter life span than wild-type controls
|
|
• over a period of 100 weeks, heterozygotes exhibit increased susceptibility to spontaneous tumor development (78% vs 53% in wild-type), with a significantly higher number of tumors per mouse than wild-type mice (1.09 vs 0.59, respectively)
• heterozygotes develop a high frequency of epithelial tumors (52%), gonad tumors (12%), and lymphomas (10%), whereas wild-type mice develop primarily age-related tumors such as lung tumors, angiomas, and sarcomas
|
|
• heterozygotes develop a high frequency of thyroid gland atypical hyperplasia and intraepithelial adenomas only after gamma-irradiation
|
|
• ~3.5% of heterozygotes develop mammary gland adenocarcinomas vs none of wild-type mice
|
 |
• 8.6% of heterozygotes develop low-grade prostate intraepithelial neoplasia vs none of wild-type mice
|
|
• tumor incidence is dramatically increased in gamma-irradiated heterozygotes (85% vs 41% in wild-type control mice), with more lymphomas and epithelial tumors detected in radiation-treated heterozygotes relative to wild-type controls or to unirradiated groups
• more lymphomas and epithelial tumors are observed in radiation-treated heterozygotes relative to wild-type controls or to unirradiated groups
• gamma-irradiation induces a high frequency of thyroid gland atypical hyperplasia and intraepithelial adenomas, and enhances the formation of lung cancers, germ cell tumors and stromal cell tumors in the testis (Leydig cell tumors) and ovary
|
|
• 8.6% of heterozygotes develop liver adenocarcinomas vs 3% of wild-type mice
|
|
• 10% of heterozygotes develop liver adenomas vs 6.5% of wild-type mice
|
|
• 10% of heterozygotes develop lymphomas that can infiltrate other organs such as the liver or small intestine and express exclusively either the B-cell marker CD45R/B220, or the T-cell marker CD3
|
|
• heterozygotes exhibit an increased frequency of lung adenocarcinomas after gamma-irradiation
|
|
• 12% of heterozygotes develop gonad tumors, including sex-cord stromal cell tumors (7%) and germ cell tumors (5%)
• heterozygotes exhibit an increased frequency of germ cell tumors and stromal cell tumors in the testis (Leydig cell tumors) and ovary after gamma-irradiation
|
|
|
• heterozygotes exhibit an increased frequency of Leydig cell tumors after gamma-irradiation
|
|
• heterozygotes exhibit an earlier tumor onset
|
|
• MEFs and tumor cellss derived from heterozygous mutant mice show an increased rate of chromosome aberrations, including chromosome end-to-end fusions and fragmentations, as well as loss of telomeres at the fusion sites
|
|
• heterozygotes irradiated with gamma-rays at a dosage of 8 Gy exhibit a significantly shorter life span than wild-type controls
|
|
• tumor incidence is dramatically increased in gamma-irradiated heterozygotes (85% vs 41% in wild-type control mice), with more lymphomas and epithelial tumors detected in radiation-treated heterozygotes relative to wild-type controls or to unirradiated groups
• more lymphomas and epithelial tumors are observed in radiation-treated heterozygotes relative to wild-type controls or to unirradiated groups
• gamma-irradiation induces a high frequency of thyroid gland atypical hyperplasia and intraepithelial adenomas, and enhances the formation of lung cancers, germ cell tumors and stromal cell tumors in the testis (Leydig cell tumors) and ovary
|
|
• heterozygotes exhibit an increased frequency of lung adenocarcinomas after gamma-irradiation
|
|
|
• 8.6% of heterozygotes develop low-grade prostate intraepithelial neoplasia vs none of wild-type mice
|
|
• 12% of heterozygotes develop gonad tumors, including sex-cord stromal cell tumors (7%) and germ cell tumors (5%)
• heterozygotes exhibit an increased frequency of germ cell tumors and stromal cell tumors in the testis (Leydig cell tumors) and ovary after gamma-irradiation
|
|
|
• heterozygotes exhibit an increased frequency of Leydig cell tumors after gamma-irradiation
|
|
• 8.6% of heterozygotes develop liver adenocarcinomas vs 3% of wild-type mice
|
|
• 10% of heterozygotes develop liver adenomas vs 6.5% of wild-type mice
|
|
• heterozygotes develop a high frequency of thyroid gland atypical hyperplasia and intraepithelial adenomas only after gamma-irradiation
|
|
• ~3.5% of heterozygotes develop mammary gland adenocarcinomas vs none of wild-type mice
|
|
|
• 8.6% of heterozygotes develop low-grade prostate intraepithelial neoplasia vs none of wild-type mice
|
|
|
• heterozygotes exhibit an increased frequency of Leydig cell tumors after gamma-irradiation
|
|
• ~3.5% of heterozygotes develop mammary gland adenocarcinomas vs none of wild-type mice
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| Nijmegen breakage syndrome | DOID:7400 |
OMIM:251260 |
J:86563 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• unlike Rad50tm2Jpt homozygotes, mice do not exhibit increased lethality or anemia at 8 months
|
|
• attrition of B-, T- and myeloid cell lineages, gut and seminiferous tubules observed in Rad50tm2Jpt homozygotes is mitigated
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• exhibit hematopoietic rescue of the abnormalities seen in homozygous Rad50tm2Jpt mice, with numbers of double-negative T cells, pro-B cells, and macrophages within 5-fold levels of wild-type levels
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 01/20/2026 MGI 6.24 |
|
|
|
||
